Literature DB >> 16217662

Comparison of topical 0.7% dexamethasone-cyclodextrin with 0.1% dexamethasone sodium phosphate for postcataract inflammation.

K Matti Saari1, Laura Nelimarkka, Virpi Ahola, Thorsteinn Loftsson, Einar Stefánsson.   

Abstract

BACKGROUND: To compare 0.7% dexamethasone-cyclodextrin aqueous eye drop solution applied once daily with 0.1% dexamethasone sodium phosphate eye drops applied three times a day for the control of postoperative inflammation after cataract surgery.
METHODS: Twenty cataract patients who underwent phacoemulsification and intraocular lens implantation were randomly divided into two postoperative treatment groups. Postoperative medication in group I included 0.1% dexamethasone sodium phosphate eye drops three times daily and in group II 0.7% dexamethasone-cyclodextrin eye drop solution once daily. Testing of visual acuity, biomicroscopic examination, applanation tonometry and laser flare cell meter (LFCM) examination were carried out before operation and days 1, 3, 7 and 21 after surgery.
RESULTS: Preoperative and postoperative visual acuity, aqueous flare and cells in biomicroscopic examination, and the mean intraocular pressure did not show any statistically significant differences between the treatment groups. LFCM examination showed that the mean postoperative photon count values (P=0.032) and the median cell count values on the 1st (P=0.014), 3rd (P=0.031), 7th (P=0.034), and 21st (P=0.0097) postoperative days in group I were more elevated than in group II.
CONCLUSIONS: 0.7% dexamethasone-cyclodextrin eye drops applied once daily is a more effective postoperative anti-inflammatory medication than 0.1% dexamethasone sodium phosphate applied three times a day. In both groups, 3 weeks after the operation the mean visual acuity was normal and intraocular pressure significantly lower than before operation. The use of 0.7% dexamethasone-cyclodextrin eye drops may be useful especially in elderly people who cannot apply themselves the eye drops onto the eye.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16217662     DOI: 10.1007/s00417-005-0124-2

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  11 in total

1.  Cyclodextrins in ophthalmic drug delivery.

Authors: 
Journal:  Adv Drug Deliv Rev       Date:  1999-03-01       Impact factor: 15.470

2.  Signs and symptoms of uveitis. I. Anterior uveitis.

Authors:  M J HOGAN; S J KIMURA; P THYGESON
Journal:  Am J Ophthalmol       Date:  1959-05       Impact factor: 5.258

3.  Dexamethasone in ophthalmology.

Authors:  D M GORDON
Journal:  Am J Ophthalmol       Date:  1959-11       Impact factor: 5.258

4.  Measurement of aqueous cells and flare in normal eyes.

Authors:  S M Shah; D J Spalton; S E Smith
Journal:  Br J Ophthalmol       Date:  1991-06       Impact factor: 4.638

5.  Electron microscopic studies on the blood-aqueous barrier of prostaglandin-treated rabbit eyes. II. Iris.

Authors:  O O Pedersen
Journal:  Acta Ophthalmol (Copenh)       Date:  1975-11

6.  Phacoemulsification with and without trabeculectomy in patients with glaucoma.

Authors:  I Yalvac; P J Airaksinen; A Tuulonen
Journal:  Ophthalmic Surg Lasers       Date:  1997-06

Review 7.  Pharmaceutical applications of cyclodextrins. 1. Drug solubilization and stabilization.

Authors:  T Loftsson; M E Brewster
Journal:  J Pharm Sci       Date:  1996-10       Impact factor: 3.534

8.  New quantitative method to determine protein concentration and cell number in aqueous in vivo.

Authors:  M Sawa; Y Tsurimaki; T Tsuru; H Shimizu
Journal:  Jpn J Ophthalmol       Date:  1988       Impact factor: 2.447

9.  Quantitative determination of aqueous flare and cells in healthy eyes.

Authors:  O M Guillén-Monterrubío; J Hartikainen; K Taskinen; K M Saari
Journal:  Acta Ophthalmol Scand       Date:  1997-02

10.  Dexamethasone-cyclodextrin-polymer co-complexes in aqueous eye drops. Aqueous humor pharmacokinetics in humans.

Authors:  J K Kristinsson; H Fridriksdóttir; S Thórisdóttir; A M Sigurdardóttir; E Stefánsson; T Loftsson
Journal:  Invest Ophthalmol Vis Sci       Date:  1996-05       Impact factor: 4.799

View more
  9 in total

Review 1.  Laser flare-cell photometer: principle and significance in clinical and basic ophthalmology.

Authors:  Mitsuru Sawa
Journal:  Jpn J Ophthalmol       Date:  2016-11-25       Impact factor: 2.447

2.  Comparison of the anti-inflammatory effects of fluorometholone 0.1% combined with levofloxacin 0.5% and tobramycin/dexamethasone eye drops after cataract surgery.

Authors:  Pei-Qing Chen; Xue-Mei Han; Ya-Nan Zhu; Jia Xu
Journal:  Int J Ophthalmol       Date:  2016-11-18       Impact factor: 1.779

Review 3.  Clinical Applications of Dexamethasone for Aged Eyes.

Authors:  Beatriz Abadia; Pilar Calvo; Antonio Ferreras; Fran Bartol; Guayente Verdes; Luis Pablo
Journal:  Drugs Aging       Date:  2016-09       Impact factor: 3.923

4.  Intraocular pressure effects of common topical steroids for post-cataract inflammation: are they all the same?

Authors:  Uwe Pleyer; Paul G Ursell; Paolo Rama
Journal:  Ophthalmol Ther       Date:  2013-09-17

5.  Corneal permeation properties of a charged lipid nanoparticle carrier containing dexamethasone.

Authors:  Junfeng Ban; Yan Zhang; Xin Huang; Guanghan Deng; Dongzhi Hou; Yanzhong Chen; Zhufen Lu
Journal:  Int J Nanomedicine       Date:  2017-02-16

6.  Investigation of Combined Cyclodextrin and Hydrogel Formulation for Ocular Delivery of Dexamethasone Acetate by Means of Experimental Designs.

Authors:  Roseline Mazet; Luc Choisnard; Delphine Levilly; Denis Wouessidjewe; Annabelle Gèze
Journal:  Pharmaceutics       Date:  2018-12-01       Impact factor: 6.321

Review 7.  Dexamethasone 0.4mg Sustained-Release Intracanalicular Insert in the Management of Ocular Inflammation and Pain Following Ophthalmic Surgery: Design, Development and Place in Therapy.

Authors:  Cassandra C Brooks; Sayena Jabbehdari; Preeya K Gupta
Journal:  Clin Ophthalmol       Date:  2020-01-13

Review 8.  Nanotechnology-based formulations to amplify intraocular bioavailability.

Authors:  Konstantinos Kagkelaris; George Panayiotakopoulos; Constantinos D Georgakopoulos
Journal:  Ther Adv Ophthalmol       Date:  2022-07-18

Review 9.  Cyclodextrins as Anti-inflammatory Agents: Basis, Drugs and Perspectives.

Authors:  Silvia Lucia Appleton; Silvia Navarro-Orcajada; Francisco Juan Martínez-Navarro; Fabrizio Caldera; José Manuel López-Nicolás; Francesco Trotta; Adrián Matencio
Journal:  Biomolecules       Date:  2021-09-19
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.